A Study of Baricitinib in Participants From 2 Years to Less Than 18 Years Old With Juvenile Idiopathic Arthritis

NCT03773978 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

220

Enrollment

INDUSTRY

Sponsor class

Conditions

Juvenile Idiopathic Arthritis

Interventions

DRUG: Baricitinib
DRUG: Placebo

Sponsor

Eli Lilly and Company